Name: Allergan Inc. (NYSE:AGN.) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Revenues as Reported

Revenues as Reported

Download chart

Allergan Inc., income statement, revenues

US$ in thousands

12 months ended:	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Eye Care Pharmaceuticals	3,257,900)	2,890,300)	2,692,200)	2,520,200)	2,262,000)
Botox®/Neuromodulators	2,230,600)	1,982,200)	1,766,300)	1,594,900)	1,419,400)
Skin Care and Other	523,600)	466,500)	326,100)	316,900)	292,000)
Specialty Pharmaceuticals	6,012,100)	5,339,000)	4,784,600)	4,432,000)	3,973,400)
Breast Aesthetics	406,700)	377,900)	377,100)	349,300)	319,100)
Obesity Intervention	—)	—)	159,500)	203,100)	243,300)
Facial Aesthetics	661,800)	477,500)	387,600)	362,700)	283,800)
Core Medical Devices	1,068,500)	855,400)	924,200)	915,100)	846,200)
Other	45,500)	3,100)	—)	—)	—)
Medical Devices	1,114,000)	858,500)	924,200)	915,100)	846,200)
Product net sales	7,126,100)	6,197,500)	5,708,800)	5,347,100)	4,819,600)

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Product net sales exhibited a consistent upward trajectory from 2010 to 2014, increasing from US$ 4,819.6 million to US$ 7,126.1 million. This growth reflects a sustained expansion across the majority of the product portfolio.

Primary Revenue Drivers: Specialty Pharmaceuticals serves as the dominant revenue contributor, growing steadily from US$ 3,973.4 million in 2010 to US$ 6,012.1 million in 2014. Botox and Neuromodulators also demonstrated consistent growth, rising from US$ 1,419.4 million to US$ 2,230.6 million over the five-year period.
High-Growth Categories: Facial Aesthetics showed substantial acceleration, increasing from US$ 283.8 million in 2010 to US$ 661.8 million in 2014. Skin Care and Other revenues experienced a significant uptick after 2012, climbing from US$ 326.1 million to US$ 523.6 million by the end of 2014.
Stable and Declining Segments: Eye Care Pharmaceuticals maintained a reliable growth pattern, expanding from US$ 2,262.0 million to US$ 3,257.9 million. Conversely, Obesity Intervention experienced a downward trend, falling from US$ 243.3 million in 2010 to US$ 159.5 million in 2012, before the segment was removed from the reporting structure in 2013.
Medical Devices Performance: Medical Devices revenue exhibited moderate volatility. After peaking at US$ 924.2 million in 2012, revenues dipped to US$ 858.5 million in 2013 before recovering strongly to reach US$ 1,114.0 million in 2014.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?